secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001104659-24-028472
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q4 ARCALYST rev $71.2M (+15% YoY); FY2024 guidance $360-380M
--------------------------------------------------------------------

- ARCALYST net product revenue $71.2M Q4 2023, $233.2M full-year 2023; ~9% of target 14,000 patients active on therapy.
- 2024 ARCALYST revenue guidance $360-380M, ~59% YoY growth at midpoint.
- Q4 net income $25.2M vs $4.5M YoY; cash $206.4M, no debt, funds operations into at least 2027.
- Abiprubart Phase 2 Cohort 4 data and new development indication expected April 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924028472/0001104659-24-028472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924028472/tm247423d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-028472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer